Bausch Health expects to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D guidance

By Public Technologies
  • Bausch Health flagged an increase to full-year 2026 adjusted EBITDA excluding acquired IPR&D guidance, based on preliminary third-quarter results.
  • The update cited stronger business performance expectations for the rest of 2026, supported by prevailing foreign exchange rates.
  • The company reported 13 consecutive quarters of year-over-year revenue growth and adjusted EBITDA growth, excluding Bausch + Lomb.
  • More detail is expected with third-quarter results on Oct. 28.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.